[O-35] Oral Session 35

[O-35-5] THIRTY-MONTH ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN IN THE ENVISION OPEN LABEL EXTENSION

^○Tomohide Adachi¹, Thapar Manish², Bonkovsky Herbert L³, Monroy Susana⁴, Ross Gayle⁵, Guillen-Navarro Encarna⁶, Cappellini Maria Domenica⁷, Minder Anna-Elisabeth⁸, Liu Shangbin⁹, Sweetser Marianne T⁹, Kuter David J¹⁰ (1.Department of Neurology and General Internal Medicine, Tokyo Saiseikai Central Hospital, Japan, 2.Massachusetts General Hospital, Boston, MA, USA, 3.Thomas Jefferson University, Philadelphia, PA, USA, 4.Wake Forest University/North Carolina Baptist Medical Center, Winston-Salem, NC, USA, 5.Instituto Nacional de Pediatria, Mexico City, Mexico, 6.Royal Melbourne Hospital, Melbourne, Victoria, Australia, 7.Medical Genetics Section, Virgen de la Arrixaca University Hospital, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain, and CIBERER-ISCIII, Madrid, Spain, 8.University of Milan, Milan, Italy, 9.Division of Endocrinology, Diabetes and Porphyria, Stadtspital Waid und Triemli, Zurich, Switzerland, 10.Alnylam Pharmaceuticals, Cambridge, MA, USA)